Abstract
Fibroblast growth factor receptor (FGFR) gene alterations are relatively frequent in lung squamous cell carcinoma (LUSC) and represent potential targets for therapy with FGFR inhibitors. However, FGFR inhibitor monotherapy is often undermined by compensatory survival pathways. In this study, a combinatorial therapeutic approach using the STAT3 inhibitor Stattic together with the pan-FGFR inhibitor AZD4547 for FGFR1-positive LUSC were assessed. The results showed that AZD4547 suppresses FGFR1 phosphorylation, triggers IL-6/STAT3 activation and induces RRM2-dependent DNA repair, limiting single-agent efficacy. Combining AZD4547 with the STAT3 inhibitor Stattic synergistically impaired cell proliferation, colony formation, and survival, and markedly enhanced apoptosis in vitro and in vivo. Mechanistically, dual inhibition disrupted the STAT3/RRM2 axis, promoting DNA damage and simultaneously provoking ROS-induced mitochondrial dysfunction. These findings nominate concurrent FGFR1 and STAT3 blockade as a promising therapeutic approach for FGFR1-positive lung squamous cell carcinomas.
Funding
This work was supported by National Natural Science Foundation of China (22407052, 82573711), Natural Science Foundation of Jiangsu Province (BK20240300), Scientific Research Project of Jiangsu Commission of Health (H2023150, MQ2024007, K2024007), Wuxi Municipal Bureau on Science and Technology (K20241060), Major Project of Wuxi Municipal Health Commission (Z202303), Wuxi Association for Science and Technology (TJXD-2024-102), Jiangsu Provincial Medical Key Discipline (Laboratory) (ZDXYS202211), And the Discipline Development Fund of the School of Medicine, Jiangnan University (Wang Xun) (1284046032240340).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval
The procedures for care and use of animals were approved by the Laboratory Animal Ethics Committee of Jiangsu Institute of Nuclear Medicine (JSINM-2024-163) and all applicable institutional and governmental regulations concerning the ethical use of animals were followed.
Consent for publication
All authors are consent for publication.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Edited by Professor Boris Zhivotovsky
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Wang, J., Hao, Y., Wang, K. et al. Stattic enhances the anti-tumor activity of AZD4547 in LUSC by blocking STAT3/RRM2-mediated DNA repair and inducing ROS-driven mitochondrial dysfunction. Cell Death Dis (2026). https://doi.org/10.1038/s41419-026-08848-1
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41419-026-08848-1
